{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Hits New 52-Week High of $5.34, Up 399%
Aclaris Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase in stock performance over the past year. The company, with a market capitalization of USD 424 million, is currently operating at a loss, highlighting its position within the volatile pharmaceuticals and biotechnology sector.
Aclaris Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout
Aclaris Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock shows a bullish trend in daily moving averages, despite recent volatility. Over the past year, it has outperformed the S&P 500, suggesting a possible positive shift in investor sentiment.
Is Aclaris Therapeutics, Inc. technically bullish or bearish?
As of August 8, 2025, Aclaris Therapeutics shows a mildly bullish trend with positive weekly indicators, despite mixed signals from daily moving averages and a year-to-date underperformance compared to the S&P 500.
Is Aclaris Therapeutics, Inc. overvalued or undervalued?
As of March 12, 2018, Aclaris Therapeutics, Inc. is considered risky and overvalued, with a Price to Book Value of 1.15 and a P/E ratio of -4.8751, making it less attractive compared to peers like Evolus, Inc. and the S&P 500.
Is Aclaris Therapeutics, Inc. overvalued or undervalued?
As of March 12, 2018, Aclaris Therapeutics, Inc. is considered overvalued with a "risky" valuation grade, highlighted by a negative P/E ratio of -3.53 and a year-to-date return of -43.95%, contrasting sharply with the S&P 500's 2.44%.
Is Aclaris Therapeutics, Inc. technically bullish or bearish?
As of May 28, 2025, the market trend is mildly bearish, indicated by daily moving averages and Bollinger Bands, despite some mildly bullish signals from the MACD and KST, suggesting a cautious approach is advisable.
Who are in the management team of Aclaris Therapeutics, Inc.?
As of March 2022, Aclaris Therapeutics, Inc.'s management team includes Dr. Neal Walker as President and CEO, along with independent directors Mr. Vincent Milano, Dr. Maxine Gowen, Mr. William Humphries, Dr. Anand Mehra, and Mr. Christopher Molineaux.
What does Aclaris Therapeutics, Inc. do?
Aclaris Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for immuno-inflammatory diseases. As of March 2025, it reported net sales of $1 million and a net loss of $15 million, with a market cap of $151.59 million.
How big is Aclaris Therapeutics, Inc.?
As of Jun 18, Aclaris Therapeutics, Inc. has a market capitalization of 151.59 million, with net sales of 17.79 million and a net profit of -130.22 million over the last four quarters. The company reported shareholder's funds of 155.55 million and total assets of 220.33 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
